CN110475563A - 一种用于抗衰老修复的干细胞制剂及其制备方法 - Google Patents
一种用于抗衰老修复的干细胞制剂及其制备方法 Download PDFInfo
- Publication number
- CN110475563A CN110475563A CN201880004897.1A CN201880004897A CN110475563A CN 110475563 A CN110475563 A CN 110475563A CN 201880004897 A CN201880004897 A CN 201880004897A CN 110475563 A CN110475563 A CN 110475563A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- preparation
- mesenchymal stem
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 57
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 46
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title abstract 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 61
- 210000004027 cell Anatomy 0.000 claims abstract description 56
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 28
- 230000008439 repair process Effects 0.000 claims abstract description 24
- 239000006166 lysate Substances 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003381 stabilizer Substances 0.000 claims abstract description 16
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960002435 fasudil Drugs 0.000 claims abstract description 14
- 239000011780 sodium chloride Substances 0.000 claims abstract description 14
- 210000003954 umbilical cord Anatomy 0.000 claims abstract description 14
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 13
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 13
- 210000002826 placenta Anatomy 0.000 claims abstract description 13
- 210000001691 amnion Anatomy 0.000 claims abstract description 9
- 239000006285 cell suspension Substances 0.000 claims description 22
- 229960003722 doxycycline Drugs 0.000 claims description 13
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 102000004142 Trypsin Human genes 0.000 claims description 11
- 108090000631 Trypsin Proteins 0.000 claims description 11
- 239000003906 humectant Substances 0.000 claims description 11
- 239000012588 trypsin Substances 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 210000001519 tissue Anatomy 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 9
- 230000002528 anti-freeze Effects 0.000 claims description 8
- 230000029087 digestion Effects 0.000 claims description 8
- 102000029816 Collagenase Human genes 0.000 claims description 7
- 108060005980 Collagenase Proteins 0.000 claims description 7
- 229960002424 collagenase Drugs 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 229940045110 chitosan Drugs 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108010019160 Pancreatin Proteins 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- 229940055695 pancreatin Drugs 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000004017 serum-free culture medium Substances 0.000 claims description 3
- 238000010008 shearing Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 5
- 230000003833 cell viability Effects 0.000 abstract description 5
- 230000037314 wound repair Effects 0.000 abstract description 4
- 238000010923 batch production Methods 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 229930195503 Fortimicin Natural products 0.000 abstract 1
- 239000004909 Moisturizer Substances 0.000 abstract 1
- BIDUPMYXGFNAEJ-APGVDKLISA-N astromicin Chemical compound O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 BIDUPMYXGFNAEJ-APGVDKLISA-N 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000001333 moisturizer Effects 0.000 abstract 1
- 238000007493 shaping process Methods 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 18
- 238000012360 testing method Methods 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 239000007798 antifreeze agent Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000036559 skin health Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- -1 cell antifreeze Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 102000055151 human KITLG Human genes 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一种用于抗衰老修复的干细胞制剂，所述的干细胞制剂包含脐带、胎盘或羊膜间充质干细胞、血小板裂解液、人血清蛋白、NaCl溶液、法舒地尔、强力霉素、高分子稳定剂、细胞防冻剂和保湿剂。一种干细胞制剂的制备方法，包括如下步骤：S1～S10，从而制得干细胞制剂。保证了有效期内的细胞活率，突破了间充质干细胞用于临床治疗的技术瓶颈；无需繁杂操作，打开即可直接用于患处，可以达到快速修复受损皮肤，提高细胞增殖活力，抗衰老，修复受损皮肤的目的。制备方法简单易操作，便于批量生产，通过本方法所获得的制剂，其体系稳定，可持续长久地发挥疗效。可应用于皮肤美容、医学整形、创伤修复领域。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/077987 WO2019169523A1 (zh) | 2018-03-05 | 2018-03-05 | 一种用于抗衰老修复的干细胞制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110475563A true CN110475563A (zh) | 2019-11-19 |
Family
ID=67846401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880004897.1A Pending CN110475563A (zh) | 2018-03-05 | 2018-03-05 | 一种用于抗衰老修复的干细胞制剂及其制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110475563A (zh) |
| WO (1) | WO2019169523A1 (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920828A (zh) * | 2020-07-07 | 2020-11-13 | 西安世越再生医学研究中心有限公司 | 基于脐带间充质干细胞用于毛发再生的冻干粉、制备方法、生发营养液及毛发再生方法 |
| CN112245454A (zh) * | 2020-10-16 | 2021-01-22 | 潍坊卡多娜生物科技有限公司 | 一种细胞疤痕修复方法 |
| CN115120617A (zh) * | 2022-07-12 | 2022-09-30 | 尹文君 | 一种含有间充质干细胞及血小板裂解液的阴道复合凝胶及其制备方法 |
| CN115463154A (zh) * | 2022-10-21 | 2022-12-13 | 上海君益禾生物医学科技有限公司 | 一种血小板裂解液和外泌体复合凝胶的制备方法及应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114042029A (zh) * | 2021-10-12 | 2022-02-15 | 成都市古月永享生物科技有限公司 | 含人多能干细胞及华通氏胶来源间充质干细胞分泌物冻干粉复合制剂、护肤品及制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155334A1 (en) * | 2008-06-20 | 2009-12-23 | Escape Therapeutics, Inc. | Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same |
| CN102670654A (zh) * | 2012-04-28 | 2012-09-19 | 北京汉氏联合干细胞研究院有限公司 | 一种用于创面修复的干细胞制剂及其制备方法 |
| CN103352026A (zh) * | 2013-07-24 | 2013-10-16 | 黑龙江天晴干细胞有限公司 | 人脐带血富血小板裂解液培养自体脐带间充质干细胞方法 |
| CN105477018A (zh) * | 2015-12-07 | 2016-04-13 | 深圳爱生再生医学科技有限公司 | 修复皮肤溃疡的干细胞制剂及其制备方法 |
| CN105708860A (zh) * | 2016-01-26 | 2016-06-29 | 深圳爱生再生医学科技有限公司 | 用于修复皮肤溃疡的干细胞制剂 |
| CN106538512A (zh) * | 2016-10-08 | 2017-03-29 | 北京汉氏联合干细胞研究院有限公司 | 一种保持冻存细胞活性的干细胞凝胶制剂及其应用 |
-
2018
- 2018-03-05 CN CN201880004897.1A patent/CN110475563A/zh active Pending
- 2018-03-05 WO PCT/CN2018/077987 patent/WO2019169523A1/zh active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155334A1 (en) * | 2008-06-20 | 2009-12-23 | Escape Therapeutics, Inc. | Differentiation of mesenchymal stem cells into fibroblasts, compositions comprising mesenchymal stem cell-derived fibroblasts, and methods of using the same |
| CN102670654A (zh) * | 2012-04-28 | 2012-09-19 | 北京汉氏联合干细胞研究院有限公司 | 一种用于创面修复的干细胞制剂及其制备方法 |
| CN103352026A (zh) * | 2013-07-24 | 2013-10-16 | 黑龙江天晴干细胞有限公司 | 人脐带血富血小板裂解液培养自体脐带间充质干细胞方法 |
| CN105477018A (zh) * | 2015-12-07 | 2016-04-13 | 深圳爱生再生医学科技有限公司 | 修复皮肤溃疡的干细胞制剂及其制备方法 |
| CN105708860A (zh) * | 2016-01-26 | 2016-06-29 | 深圳爱生再生医学科技有限公司 | 用于修复皮肤溃疡的干细胞制剂 |
| CN106538512A (zh) * | 2016-10-08 | 2017-03-29 | 北京汉氏联合干细胞研究院有限公司 | 一种保持冻存细胞活性的干细胞凝胶制剂及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| 方少霞等: "壳聚糖-明胶海绵与脐带间充质干细胞修复皮肤伤口的差异 ", 《中国组织工程研究》 * |
| 李云霞: "脐带间充质干细胞对皮肤创伤愈合影响的实验研究 ", 《中国美容医学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920828A (zh) * | 2020-07-07 | 2020-11-13 | 西安世越再生医学研究中心有限公司 | 基于脐带间充质干细胞用于毛发再生的冻干粉、制备方法、生发营养液及毛发再生方法 |
| CN112245454A (zh) * | 2020-10-16 | 2021-01-22 | 潍坊卡多娜生物科技有限公司 | 一种细胞疤痕修复方法 |
| CN115120617A (zh) * | 2022-07-12 | 2022-09-30 | 尹文君 | 一种含有间充质干细胞及血小板裂解液的阴道复合凝胶及其制备方法 |
| CN115120617B (zh) * | 2022-07-12 | 2024-06-21 | 长沙市中心医院 | 一种含有间充质干细胞及血小板裂解液的阴道复合凝胶及其制备方法 |
| CN115463154A (zh) * | 2022-10-21 | 2022-12-13 | 上海君益禾生物医学科技有限公司 | 一种血小板裂解液和外泌体复合凝胶的制备方法及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019169523A1 (zh) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110475563A (zh) | 一种用于抗衰老修复的干细胞制剂及其制备方法 | |
| CN106109496B (zh) | 人脐带间充质干细胞提取物冻干粉及制备方法 | |
| CN102670654A (zh) | 一种用于创面修复的干细胞制剂及其制备方法 | |
| CN113509590B (zh) | 外泌体联合透明质酸的伤口敷料及其制备方法和应用 | |
| KR20070122316A (ko) | 주사용 인체 연조직 충전제 및 이의 제조 방법 | |
| CN101757691A (zh) | 一种组织工程角膜的制备方法 | |
| US20180236003A1 (en) | Cell Expansion Methods and Therapeutic Compositions | |
| US20190290690A1 (en) | Compositions comprising adjustable concentrations of growth factors derived from blood serum and clot hypoxia-conditioned medium and methods of their production | |
| CN116515743B (zh) | 一种毛囊修复蛋白组合物及其制备方法和其应用 | |
| CN108057116A (zh) | 干细胞组合物在皮肤损伤治疗药物中的应用 | |
| WO2018150440A1 (en) | Stem cell conditioned media for clinical and cosmetic applications | |
| CN110623917A (zh) | 一种包载干细胞复合因子的美容及皮肤修复透明质酸钠凝胶 | |
| CN111821250A (zh) | 抗衰老组合物及其制备方法与应用 | |
| CN105477626A (zh) | 混合干细胞制剂及其制备方法 | |
| CN108642002A (zh) | 一种无血清驯化培养人间充质干细胞的方法 | |
| CN109771694A (zh) | 自组装多肽纳米纤维水凝胶支架材料的制备方法及应用 | |
| CN111956668B (zh) | 一种皮肤再生修复细胞组合物及制备方法 | |
| US20010006813A1 (en) | Methods and compositions for the preparation of cell transplants | |
| CN113842398B (zh) | 一种用于促进外伤愈合的脐带间充质干细胞外用凝胶、给药方法和应用 | |
| CN102172337B (zh) | 具有皮脂腺样结构的组织工程皮肤及其制备方法 | |
| CN108066750A (zh) | 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途 | |
| CN113274410A (zh) | 外泌体水凝胶复合物在制备修复皮肤瘢痕的药物中的应用 | |
| KR20100101715A (ko) | 피부 충전제 조성물 | |
| CN108066824A (zh) | 一种制备表皮缺损治疗药物的新方法 | |
| CN115252539A (zh) | 一种用于负载干细胞的多肽水凝胶及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191119 |